ClinicalTrials.gg

Program

resiquimod

Also written as “BDB-001 injection”, “EIK1001” and “BDB-001 Injection”.

Its studies are mostly in Neoplasms · Neoplasm Metastasis · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · COVID-19 · Hidradenitis Suppurativa, led by 2 companies.

Furthest: phase 3, since Jun 26, 202014 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Staidson (Beijing) Biopharmaceuticals81 open or runningphase 3since Jun 26, 2020Jun 26, 2020Apr 16, 2027phase 3 · NCT07168161
Eikon Therapeutics63 open or runningphase 3since Nov 18, 2024Feb 28, 2018Dec 2026phase 2 · NCT06246110

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 28, 2018First study: phase 1 study in NeoplasmsNew to Eikon TherapeuticsEikon Therapeutics · NCT03486301 · 87 enrolled · United States
  2. Dec 10, 2019Phase 1 study in NeoplasmsEikon Therapeutics · NCT04196530 · 40 enrolled · United States
  3. Jun 26, 2020Staidson (Beijing) Biopharmaceuticals's first study: phase 3 study in COVID-19New to Staidson (Beijing) BiopharmaceuticalsStaidson (Beijing) Biopharmaceuticals · NCT04449588 · 369 enrolled · Bangladesh, China, India and more
  4. Jan 18, 2021Phase 2 study in NeoplasmsEikon Therapeutics · NCT04819373 · 1 enrolled · United States
  5. Jun 23, 20212 phase 2 studies in Hidradenitis SuppurativaStaidson (Beijing) Biopharmaceuticals · NCT05103423, NCT05093855
  6. Aug 22, 2021Phase 1 study in COVID-19Staidson (Beijing) Biopharmaceuticals · NCT05075304 · 18 enrolled · China
  7. Dec 2, 2021Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisStaidson (Beijing) Biopharmaceuticals · NCT05197842 · 93 enrolled · China
  8. Apr 29, 20222 phase 1 studies in HealthyStaidson (Beijing) Biopharmaceuticals · NCT05361005, NCT05360927
  9. Jan 30, 2024Phase 2 study in Neoplasm MetastasisEikon Therapeutics · NCT06246110 · 70 enrolled · United States
  10. Nov 18, 2024Phase 3 study in Neoplasm MetastasisEikon Therapeutics · NCT06697301 · 740 planned · United States, Australia, Austria and more
  11. Sep 4, 2025Phase 3 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisStaidson (Beijing) Biopharmaceuticals · NCT07168161 · 300 planned · China
  12. Jan 22, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungEikon Therapeutics · NCT07365319 · 750 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 2026Primary completion: phase 2 study in Neoplasm MetastasisEikon Therapeutics · NCT06246110
  2. Apr 16, 2027Primary completion: phase 3 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisStaidson (Beijing) Biopharmaceuticals · NCT07168161
  3. Dec 2035Primary completion: phase 3 study in Neoplasm MetastasisEikon Therapeutics · NCT06697301
  4. Dec 31, 2035Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungEikon Therapeutics · NCT07365319

TargetBeta

TLR7 →TLR8 →read by rule
“The sulfate salt form of resiquimod, a toll-like receptor type 7 and 8 (TLR7/8) agonist, ”NCIt, by rule
“Toll-like receptor 8 agonist; Toll-like receptor 7 agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
enpatoranruleMerck KGaA, Darmstadt, Germanyphase 312
afimetoranruleBristol-Myers Squibbphase 312

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07365319Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingEikon TherapeuticsDec 31, 2035750
NCT07168161Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · China3RecruitingStaidson (Beijing) BiopharmaceuticalsApr 16, 2027300
NCT06697301Neoplasm Metastasis · United States, Australia, Austria and more3RecruitingEikon TherapeuticsDec 2035740
NCT06246110Neoplasm Metastasis · United States2Active, not recruitingEikon TherapeuticsDec 202670
NCT05361005Healthy · China1CompletedStaidson (Beijing) BiopharmaceuticalsMay 8, 202033
NCT05360927Healthy · China1CompletedStaidson (Beijing) BiopharmaceuticalsDec 25, 202028
NCT05197842Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · China2CompletedStaidson (Beijing) BiopharmaceuticalsMar 19, 202593
NCT05075304COVID-19 · China1TerminatedStaidson (Beijing) BiopharmaceuticalsApr 14, 202018
NCT05103423Hidradenitis Suppurativa · China2CompletedStaidson (Beijing) BiopharmaceuticalsJul 7, 202350
NCT05093855Hidradenitis Suppurativa · China2CompletedStaidson (Beijing) BiopharmaceuticalsAug 22, 202341
NCT04819373Neoplasms · United States2CompletedEikon TherapeuticsApr 1, 20231
NCT04449588COVID-19 · Bangladesh, China, India and more3TerminatedStaidson (Beijing) BiopharmaceuticalsMar 26, 2024369
NCT04196530Neoplasms · United States1CompletedEikon TherapeuticsJul 31, 202440
NCT03486301Neoplasms · United States1CompletedEikon TherapeuticsMar 31, 202487

How it is read

Names in the registry

  • “BDB-001 injection”, 7 entries
  • “EIK1001”, 3 entries
  • “BDB-001 Injection”, 3 entries
  • “BDB001 (EIK1001)”, 2 entries
  • “BDB001”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.